SA
MYGN

Myriad Genetics, Inc. specializes in genetic testing and precision medicine, focusing on oncology, women's health, and hereditary cancer testing. The company operates primarily in the United States, leveraging its proprietary testing platforms and extensive genetic database to provide actionable insights for patient care.

HealthcareMedical - Diagnostics & Researchlow - The company has high fixed costs associated with lab operations and R&D, leading to limited operating leverage.

Business Overview

01Oncology testing - 60%
02Women's health testing - 30%
03Other genetic tests - 10%

Myriad generates revenue through its genetic testing services, which are often reimbursed by insurance providers. The company has a competitive advantage due to its established brand reputation, proprietary technology, and extensive database of genetic information that enhances the accuracy of its tests.

What Moves the Stock

Changes in reimbursement policies for genetic tests

Regulatory approvals for new tests

Market adoption rates of precision medicine

Competitive landscape shifts in genetic testing

Watch on Earnings
Revenue growth rateGross margin percentageOperating margin

Risk Factors

Technological disruption from advancements in genetic testing technology

Regulatory changes affecting testing approvals and reimbursement

Increased competition from emerging genetic testing companies

Potential market share loss to larger diagnostic firms

Negative net margins leading to potential liquidity concerns

Debt levels may impact financial flexibility

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The demand for genetic testing can be influenced by overall healthcare spending, which is correlated with GDP growth.

Interest Rates

Interest rates affect Myriad's cost of capital and can influence investment in R&D; higher rates may compress valuations.

Credit

minimal - Myriad's operations are not heavily reliant on credit markets.

Live Conditions
Dow Jones FuturesRussell 2000 FuturesS&P 500 Futures

Profile

growth - Investors may be attracted to the potential for revenue growth in the precision medicine space.

high - The stock has shown significant price fluctuations, reflecting its operational challenges and market sentiment.

Key Metrics to Watch
Oncology testing revenue growth
Women's health testing revenue growth
Gross margin percentage
Regulatory approval timelines for new tests
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.